The key question we should ask is whether these Guiding Principles will help break the failed logic applied until now, which has prioritised forced eradication and added development as an afterthought.
Examining the evolution of Irish drug policy, the report explores the country’s national strategies; the legal context within which they operate; the public funds spent, or committed, to implement them; and the political bodies and mechanisms set up to coordinate the response to the problem.
This briefing paper aims to shift the focus of the debate on policing and HIV-related outcomes and explore more positive relationships and the related benefits to be derived by police engaging with people who inject drugs.
Focused deterrence strategies seek to minimise the most pernicious behaviour of criminal groups (such as violence) while tolerating less harmful activities.
The policy brief summarizes key findings from an assessment of hepatitis C treatment accessibility in Eastern Europe and Central Asia (EECA) undertaken by the Eurasian Harm Reduction Network (EHRN). Based on formulated recommendations on how to remove the barriers to treatment access.
This UNODC report analyses the dynamics of key crime in West African markets and provides recommendations for the international community to tackle cocaine, methamphetamine and heroin trafficking, as well as other drug-related problems.
Youth RISE is a youth-led network promoting evidence based drug policies and harm reduction strategies with the meaningful involvement of young people who use drugs and are affected by drug policies.
This February 2013 newsletter focuses on drug policy developments and harm reduction services in Montenegro, OST treatment in Albania or the development of local responses to the emerging HIV threat among users of legal high in Romania.
The aim of this second TEDI' s report is to present the results of the data that has been gathered, analysed and compared by six harm reduction groups during the seven-month period June–December 2012 in five countries.
Current drug policies has increased the risks associated with drug use, tilting the market towards ever more potent and risky products often cut with contaminants, and encouraging high-risk behaviours.
